Barbara Fletcher

The development of drugs that target angiogenesis and signal transduction pathways in the treatment of metastatic renal cell carcinoma (RCC) has led to improved survival rates for patients.

The treatment of advanced renal cell carcinoma (RCC) remains a major challenge for clinicians. However, according Daniel J. George, MD, the progress being made in understanding RCC tumor biology is already helping us to discover better, more effective treatments.